Insights

3 of the best ASX results from week three of reporting season

These results were among the best from week three of reporting season…
The post 3 of the best ASX results from week three of reporting season appeared first on The Motley Fool Australia. –

Reporting season went up another gear last week when an even larger number of companies released their latest results.

Three of the best results from last week are summarised below. Here’s what they reported:

CSL Limited (ASX: CSL)

Despite facing a number of headwinds, this biotherapeutics giant delivered a full year result ahead of expectations last week. For the 12 months ended 30 June, CSL reported a 9.6% increase in constant currency revenue to US$10,026 million and a 10% lift in profit after tax to US$2,307 million. The latter compares to its guidance of 3% to 8% growth. And while plasma collection headwinds are expected to weigh on its performance in FY 2022, leading to a decline in profit, this was largely expected by the market. Overall, the result went down well with Morgans. In response, the broker retained its add rating and lifted its price target on the company’s shares by 8% to $324.40.

Domino’s Pizza Enterprises Ltd (ASX: DMP)

The Domino’s share price raced to a record high last week after investors responded positively to its full year results. In FY 2021, the pizza chain operator delivered a 14.6% increase in network sales to $3.74 billion and a 29.2% jump in net profit after tax to $188.2 million. This was driven by new store openings and solid same store sales growth across its ANZ, European, and Asian operations. Positively, FY 2022 has started strongly, with network sales up 7.7% year to date compared to the same period last year. The team at Citi were impressed. In response, the broker retained its buy rating and lifted its price target to $159.05.

Pro Medicus Limited (ASX: PME)

The Pro Medicus share price also jumped to a record high last week following the release of its full year results. In FY 2021, the healthcare technology company delivered a 19.5% increase in revenue to $67.9 million and a 33.7% jump in net profit after tax to $30.9 million. This was driven partly by the implementation of a number of multi-year contract wins from major healthcare institutions. Morgans was happy with its result. It lifted its price target on the company’s shares from $49.00 to $62.00. However, for valuation reasons, it has held firm with its hold rating. The Pro Medicus share price ended the week at $65.85.

The post 3 of the best ASX results from week three of reporting season appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

More reading

These were the best performing ASX 200 shares last week

Brokers name 3 ASX shares to buy today

CSL (ASX:CSL) share price lifts despite UniSuper divestment threat
CSL (ASX:CSL) share price charges higher on bullish broker note
Top brokers name 3 ASX shares to sell today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. and Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended Dominos Pizza Enterprises Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!